It has only been within the last few years that insights have been gained into the remarkable diversity of functions of the adenovirus early transcription region 4 (E4) products. The polypeptide encoded by E4 open reading frame 4 (E4orf4) has emerged as an enigmatic product. Although it accomplishes certain functions that propel viral replication, it has also been shown to be highly toxic, an eect that could dampen the infectious cycle, but that also might serve to facilitate release of viral progeny. When expressed alone, E4orf4 induces a novel form of p53-independent apoptosis in cancer cells but not in normal human cells, thus making it of potential use in cancer gene therapy. In addition, knowledge of its mechanism of action, especially with regard to its interaction with protein phosphatase 2A (PP2A), could provide insights to develop new small molecule anti-cancer drugs. Thus future studies on E4orf4 should be both informative and potentially valuable therapeutically. In this study we review the current status of knowledge on E4orf4. Oncogene (2001) 20, 7855 ± 7865.
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Early region 4 (E4)
The E4 transcription unit contains at least seven open reading frames (Freyer et al., 1984; Herisse et al., 1981; Virtanen et al., 1984) that, until recently, appeared to encode functions with no obvious common theme. It is now clear that most, if not all, yield products that play important roles in furthering both early and late stages of the adenovirus infectious cycle (for review see TaÈ uber and Dobner, this issue). Some, including E4orf1, E4orf3 and E4orf6, also can induce or enhance cell transformation either alone or in cooperation with products of early region 1A and 1B (E1A and E1B).
E4orf4 structure and synthesis
The product of E4 open reading frame 4 (E4orf4; also reviewed in Kleinberger, 2000) is a small polypeptide, in the case of Ad2 or Ad5, consisting of 114 residues (see Figure 1 ). It shares no extensive sequence homology with any known protein. E4orf4 contains a highly basic sequence (in Ad2, R 66 AKRRDRRRR; consensus RxKRRxRRRR); however, it is still unclear if this sequence serves as a nuclear targeting or retention signal. It also contains a proline-rich sequence near the amino terminus (in Ad2, M 1 VLPALPAPP; consensus MxxPxLPxPP) that could potentially represent an SH3-binding site. Apart from small regions at the amino and carboxy termini, deletion of even short portions of E4orf4 yields products that are generally non-functional and often somewhat unstable (Marcellus et al., 2000) . These results suggest that the central core of the E4orf4 protein may contain considerable tertiary structure of functional importance. E4orf4 mRNA is produced from the E4 promoter early after infection as one of seven E4 transcripts; however, transcription of E4 ceases during the late phase. Nevertheless, E4orf4 persists at constant levels even late in infection as it is highly stable (Boivin et al., 1999) . Studies on post-translational modi®cations of E4orf4 have not been carefully pursued, but low levels of both phosphoserine and phosphothreonine have been detected in E4orf4 isolated from infected cells (J Lee and PE Branton, unpublished) .
Early studies of E4orf4 function using mutants
Early studies that employed mutants defective in individual E4 products indicated that E4orf4 (and most other E4 products) is not essential for virus growth (Halbert et al., 1985) . E4orf4 function was linked to viral DNA synthesis in studies showing that viruses lacking E4orf4 replicated viral DNA eciently, but that a mutant expressing E4orf4 as the only E4 product was highly defective (Bridge et al., 1993) . Whether these eects are due to the toxicity of E4orf4, discussed below, and/or to the essential role of other E4 products in DNA synthesis is not clear.
Studies in S49 mouse lymphoma cells showed that expression of the adenovirus E1A protein and addition of dibutyryl cAMP induces transcription factor AP-1 activity through increased expression of genes encoding its constituents, JunB and c-Fos, and increased translation of c-Fos mRNA (Engel et al., 1988; MuÈ ller et al., 1989) . At fairly early times during infection all such activities are reduced, and this reduction was shown to be due to the E4orf4 protein (MuÈ ller et al., 1989) . E4orf4 also negatively regulates expression of the E4 promoter (Bondesson et al., 1996) , and more recently it has been found to reduce expression of the viral E2 promoter regulated by transcription factor E2F (Mannervik et al., 1999) . Thus E4orf4 elicits a strong dampening eect on E1A-activated transcription. E4orf4 also plays a key role in controlling the splicing pattern of late adenovirus L1 mRNAs (Kanopka et al., 1998) .
E4orf4 interacts with protein phosphatase 2A (PP2A)
The major ®rst insight into the mechanism of action of E4orf4 came with the observation that immunoprecipitates prepared using anti-E4orf4 antibodies also contain the Ba regulatory subunit as well as the A and C subunits of the serine/threonine phosphatase PP2A (Kleinberger and Shenk, 1993) . It is likely, though not proven biochemically, that a direct interaction takes place between E4orf4 and Ba. This ®nding suggested a hypothesis, which persists to the present, that the biological eects of E4orf4 are induced by a change in PP2A activity, substrate speci®city, or localization following interaction with the B subunit of the holoenzyme.
Results from several early studies support the idea that changes in phosphorylation underlie E4orf4 function. Downregulation of AP-1 activity by E4orf4 is associated with hypophosphorylation of both c-Fos and the E1A protein (MuÈ ller et al., 1992) . Phosphorylation of c-Fos regulates its activation or repression functions as a component of the heterodimeric transcription factor AP-1. Thus the downregulation of transcription of the junB and c-fos genes, and thus The ability of these mutants to induce cell death and interact with PP2A are correlated and grouped as class I, class II, wild-type * or unstable * (Marcellus et al., 2000) . Below are point mutants as determined from separate studies and their ability to promote apoptosis in transformed cell lines. (+)=induces apoptosis at wild type levels; (7)=no apoptosis; (+/7)=induces intermediate level of apoptosis (Shtrichman et al., 1999; A®® et al., 2001) AP-1 activity, could result from underphosphorylation of c-Fos, either directly or indirectly by E4orf4-regulated PP2A. The time required for this eect on AP-1 suggested that PP2A may play an indirect role, possibly through downregulation of protein kinase(s) that act on c-Fos sites (Kleinberger and Shenk, 1993; MuÈ ller et al., 1992) . Nonetheless, treatment of cells with okadaic acid, a relatively speci®c inhibitor of PP2A, blocks the ability of E4orf4 to induce c-Fos hypophosphorylation (Kleinberger and Shenk, 1993) . The basis for E4orf4-induced decreases in c-Fos translation are not known, but perhaps suggest that E4orf4 regulates protein synthesis.
Although the mechanism of E4orf4-mediated eects on E2F are not understood (Mannervik et al., 1999) , some insights have been gained on regulation of E4 expression by E4orf4. It is believed that at least two phosphorylation events control this process. E4 promoter expression is regulated by ATF2 and more stringently by transcription factor E4F, which binds to two specialized ATF2 sites. E4orf4 downregulation of E4 expression was found to be inhibited by okadaic acid, suggesting that the interaction between E4orf4 and PP2A may be involved (Bondesson et al., 1996) . It is presumed therefore that changes in phosphorylation of a transcription factor critical for the E4 promoter is involved. In this regard, E4F is known to be regulated by E1A through phosphorylation (Fernandes and Rooney, 1997) , and thus could represent a key E4orf4-PP2A target. E4 transcription also absolutely requires E1A proteins, speci®cally the CR3 transactivation region and auxiliary region AR1 (Bondesson et al., 1992) . E4orf4 induces a loss in phosphorylation of E1A protein (MuÈ ller et al., 1992) , and these sites were mapped to serine residues 185 and 188, which lie within the CR3-AR1 region (Whalen et al., 1997) . Further, this study showed that hyperphosphorylation of these E1A sites through expression of constitutively active MAPKK increased transcription from the E4 promoter but not from that of E3. Although another study suggested a reduced importance of E1A phosphorylation (Bondesson et al., 1996) , these results suggested that hypophosphorylation of these sites in E1A protein could play a key role in E4orf4/PP2A-induced downregulation of E4 expression. As was the case with c-Fos, it is unclear if E4orf4-regulated PP2A dephosphorylates E1A protein or if the eect is indirect and via eects on the E1A kinase, believed to be a MAPK-like enzyme (Whalen et al., 1997) . It is tempting to postulate that downregulation of E4 expression serves to maintain low levels of E4orf4, which is highly toxic (see below).
A ®nal link between PP2A and E4orf4 function concerns regulation of L1 mRNA splicing late in infection. E4orf4 enhances usage of the distal L1 acceptor site to induce the accumulation of IIIa mRNA at the expense of the 52,55K mRNA formed via the proximal site (Kanopka et al., 1998) . SR splicing factors inhibit IIIa pre-mRNA splicing by binding to the intronic IIIa repressor element (Kanopka et al., 1996) . During adenovirus infection some SR factors become functionally inactivated as IIIa repressors through virus-induced dephosphorylation, thus enhancing L1-IIIa mRNA formation (Kanopka et al., 1998) . It has recently been shown that E4orf binds, either directly or indirectly, to a subset of hyperphosphorylated SR proteins, and that E4orf4 mutants that fail to interact with the B subunit of PP2A fail to activate IIIa splicing (Estmer-Nilsson et al., 2001) . These results suggest that E4orf4-associated PP2A may be responsible for dephosphorylating these SR factors to promote a switch in the late adenovirus splicing pattern. Thus eects of E4orf4 on both transcription and splicing could be mediated through dephosphorylation by E4orf4-regulated PP2A.
A curious result is the apparent inhibition by E4orf4 of CTL lysis of cells infected by adenovirus vectors and harboring E4orf4 in the vector backbone (Kaplan et al., 1999) . This response was unaected by treatment with okadaic acid, suggesting that PP2A is not involved.
Structure and function of PP2A
PP2A is an abundant serine/threonine phosphatase. Figure 2 shows that its holoenzyme is a trimer of catalytic C subunit, and A and B regulatory subunits (Janssens and Goris, 2001) . The A subunit is a 65 kDa rod-like protein containing 15 non-identical repeats. The 37 kDa catalytic C subunit binds to repeats 11 ± 15, whereas B subunits bind to repeats 1 ± 10. A and C are ubiquitous, and each exists in two isoforms. Thus far about 20 B subunit variants have been cloned and exist in three classes. The B (B55) class comprises four (Healy et al., 1991; Khew-Goodall et al., 1991; Pallas et al., 1992; Zolnierowicz et al., 1994) . The B' (B56) class (a, b, g, d, e) is composed of at least 13 isoforms (Csortos et al., 1996; McCright et al., 1996a; McCright and Virshup, 1995; Tanabe et al., 1996; Tehrani et al., 1996; Zhao et al., 1997; Zolnierowicz et al., 1996) . The B'' class contains at least three isoforms PR72/130, PR48 and PR59 (Hendrix et al., 1993; Voorhoeve et al., 1999; Yan et al., 2000) . Recently, two additional B-type subunits, S/G 2 nuclear autoantigen and striatin, have been identi®ed and represent a putative B''' (B93/110) family (Moreno et al., 2000) . Dierent classes of B subunits share little or no homology, yet all bind to a similar region of the A subunit. Recent evidence has shown that binding of B subunits to the AC core is regulated by both phosphorylation and methylation of the C subunit (Evans and Hemmings, 2000; Wei et al., 2001; Wu et al., 2000) . B subunits can be located either in the cytoplasm or nucleus. Some, like Ba, are expressed in many tissues, while others have more limited expression. B subunits function not only in de®ning the substrate speci®city of PP2A but also in intracellular targeting, tissue speci®-city, and as binding partners for interacting proteins. PP2A substrates include proteins involved in basal metabolism, DNA replication, cell proliferation, and cell cycle regulation (Janssens and Goris, 2001 ). The AC (core) dimer is also present at reasonable levels but lacks substrate speci®city (Kremmer et al., 1997) . A number of important PP2A substrates involved in growth regulation have been identi®ed, such as cyclin-dependent kinases (Cdks) and their substrates, including possibly the retinoblastoma tumor suppressor (Agostinis et al., 1992; Ferrigno et al., 1993) . PP2A downregulates the MAPK pathway by dephosphorylating MAPK and MAPKK (Frost et al., 1994; Karin and Hunter, 1995; Sontag et al., 1993) . There is also mounting evidence that both the Aa and Ab subunits may function as tumor suppressors as they are frequently mutated in melanomas, lung and breast carcinomas and gliomas (Calin et al., 2000; Wang et al., 1998; Colella et al., 2001) .
Interaction of small DNA tumor virus tumor antigens with PP2A
In addition to adenovirus E4orf4, tumor antigens encoded by other small DNA tumor viruses also bind to PP2A and these interactions may be of signi®cance in transformation or immortalization by these agents. Small T antigens (ST) of SV40 and polyoma and the polyoma middle T antigen (MT) bind PP2A to form stable ST/MT-A-C heterotrimers with the release of free B subunit (Pallas et al., 1990; Walter et al., 1990) . Interactions of PP2A with ST enhance cell survival, and with MT they are required for binding of c-Src, PI3' kinase and Shc, functions that are essential for oncogenesis (Campbell et al., 1995; Glenn and Eckhart, 1995) . T antigens bind to the A subunit at repeats 3 ± 6 (SV40-ST) or 2 ± 8 (polyoma ST/MT) and, as these sites overlap those utilized by the B subunit, these interactions displace B. Binding destroys the holoenzyme and inhibits overall core enzyme activity; however, this PP2A complex appears to act on SV40 ST antigen and p53 (Scheidtmann et al., 1991; Yang et al., 1991) . It is generally assumed that the biological eects of these interactions are to modify or inhibit PP2A activity; however, it remains possible that released free B subunits carry out an as yet unidenti®ed function. It is still unclear whether or not T antigenmodi®ed PP2A retains activity against some cellular substrates. One possibility is that global inhibition of PP2A by SV40 and polyoma tumor antigens prevents activation by PP2A of pro-apoptotic cellular factors, thus enhancing cell survival and transformation. It is also possible that the modi®ed complex is redirected to substrates which, when dephosphorylated, promote survival. As mentioned above, E4orf4 may activate PP2A, and as discussed in detail below, one consequence is to induce cell death by apoptosis.
Features of apoptosis
Apoptosis is a genetically-regulated killing process characterized by shrinkage and rounding of cells, disruption of the cytoskeleton, condensation of chromatin, cleavage of DNA to nucleosome sized fragments, cytoplasmic vacuolization and blebbing, and in the ®nal stages, fragmentation of the cell into membrane-bound apoptotic bodies that are engulfed by neighboring cells. In this way cells containing genotoxic damage, imbalances in growth (such as cancer cells), or those challenged by virus infection are eliminated from the host. Apoptosis is often regulated at two checkpoints (Gross et al., 1999; Korsmeyer, 1999) . Common to most (but not all) apoptotic pathways is the activation of caspases (Salvesen and Dixit, 1999) . Caspases represent a unique class of pro-proteases that can be activated directly, as with TNFR and Fas, which, after ligand binding, form signaling complexes that bind and activate initiator caspases (Nagata, 1997) . With many apoptosis inducers, including p53, activation depends on a signal from an upstream checkpoint regulated by dimerization of a family of integral membrane proteins related to Bcl-2. Homodimerization of Bcl-2 family member Bax promotes caspase activation that is prevented by Bcl-2 and related proteins that heterodimerize with Bax to prevent formation of Bax-Bax homodimers. Another Bcl-2-related protein, Bad, triggers apoptosis by binding Bcl-2, thus preventing heterodimerization with Bax. Cells are maintained by`survival factors' and the positive balance of death suppressors. Dimerization occurs via Bcl-2 homology (BH) domains. Bcl-2 family members are components of membrane complexes in mitochondria and the endoplasmic reticulum and may constitute channels that regulate release of initiators of caspases, like cytochrome c. Activation of the caspase cascade results in cleavage and activation of enzymes that kill the cell.
Signaling and phosphorylation in the apoptotic pathway
Many`survival factors' are growth factors that regulate cell proliferation through phosphorylation involving tyrosine kinase receptors and serine/threonine kinase cascades. Bcl-2 and Bcl-X L are both positively and negatively regulated by serine phosphorylation (Yamamoto et al., 1999) . Phosphorylation of pro-apoptotic Bad blocks binding to Bcl-2 and promotes association with 14-3-3 protein in the cytoplasm (Zha et al., 1996) . PI3' kinase is linked with phosphorylation of Bad. PI3' kinase is activated by binding to phosphotyrosylated receptors and resulting phosphoinositides recruit the kinases Akt and PDK1 via PH domains (Hemmings, 1997a,b) . PDK1 activates Akt by phosphorylation and Akt subsequently translocates and inactivates Bad by phosphorylating some sites (Datta et al., 1997; del Peso et al., 1997) . Thus phosphorylation of Bcl-2 and Bad can promote cell survival. Therefore dephosphorylation of these proteins by PP2A or other phosphatases could promote apoptosis.
Induction and suppression of apoptosis by adenovirus products
Infection of cells by many viruses induces apoptosis (Roulston et al., 1999; Teodoro and Branton, 1997) . In the case of adenoviruses, the principal cause for this induction is the E1A protein (see Figure 3) . A major role therefore of the E1B55K, E1B19K and E4orf6 products is to block E1A toxicity long enough to allow high virus yields. This eect is also evident in transformation of rodent cells, as expression of E1A alone results in rare transformants that normally die from apoptosis. The best understood mechanism of E1A-induced apoptosis relates to enhanced stabilization and activation of p53. Such stabilization results from interactions of E1A proteins with either the p300/ CBP histone acetyl transferases or the RB tumor suppressor family (Chiou and White, 1997; Querido et al., 1997) . The mechanism of the latter is related to enhanced expression of Arf by E2F-1 and thus inhibition of Mdm2-mediated p53 degradation and induction of p53-dependent apoptosis (de Stanchina et al., 1998) . Viability of infected or transformed cells in the presence of E1A is enhanced by the E1B55K protein, which binds to and blocks p53 function; by the E1B19K protein, which functions as a Bcl-2 analog to suppress apoptosis; by the E4orf6 protein, which binds to p53 and inhibits p53 transactivation activity; and by E4orf6/E1B55K complexes, which target p53 for degradation via a Cul5-mediated ubiquitination pathway (see review by TaÈ uber and Dobner in this issue).
Induction of apoptosis by E4orf4
Because E1A products appeared to induce apoptosis largely via p53, our group reasoned that expression of E1A in p53-null cells should not result in apoptotic cell death. It was found that such was the case in p53 knockout' mouse cells infected with adenoviruses expressing only a CR3-defective 243R E1A product. Due to the absence of the CR3 transactivation region, this virus expresses E1A and E1B products, low levels of E2 proteins, but almost no E3 or E4 products. Surprisingly, a similar experiment conducted with viruses expressing full length E1A induced apoptosis in p53-null cells, as evidenced by the generation of DNA ladders and chromatin condensation characteristic of apoptosis (Teodoro et al., 1995) . These results suggested that apoptosis was caused not by E1A but rather by another viral or cellular product expressed under the control of the E1A transactivation region. To identify this product studies were conducted in E1A-expressing p53-null mouse cells infected with adenovirus vectors lacking various portions of the viral genome, and the results indicated that one or more E4 proteins were responsible (Marcellus et al., 1996) . Using a series of E4 mutants, the killing function was mapped to E4orf4 . With virus in which E4orf4 or E4orf4 plus either E4orf6 or E4orf3 were the only E4 products, cell death was induced at high eciency. Expression of E4orf4 alone in the absence of all other Ad products also induced p53-independent cell death by apoptosis . Similar eects were observed with E4orf4 products from all classes of human adenoviruses (Marcellus et al., 2000) . We also established an E4orf4-inducible CHO cell line and showed that such cells die upon induction of E4orf4, exhibiting classic apoptotic features including DNA degradation, chromatin condensation, and the presence of phosphatidyl serine on the outer cell membrane as determined by annexin V staining . Curiously, apoptosis was not aected by the pan-caspase inhibitor zVAD-fmk, and thus did not appear to involve signi®cant activation of caspases (see more below). As this work was being carried out, the group of Tamar Kleinberger was continuing studies on E4orf4 and they showed independently that E4orf4 induces p53-independent apoptosis (Shtrichman and Kleinberger, 1998) .
The ®nding that E4orf4 is a toxic protein was originally surprising, as earlier work showed that a viral mutant lacking E4orf4 produced an early cytotoxic eect characterized by the release of cells from the monolayer (MuÈ ller et al., 1992) . In retrospect, this result is dicult to interpret because, as discussed above, E4orf4-null viruses are defective in several aspects of the lytic cycle and overexpress other E4 products. Thus such eects could alter cell physiology and lead to reduced attachment to the plate. Analysis of these cells showed that they were not dead, as indicated by Trypan Blue exclusion, and in fact E4orf4-null viruses exhibit a prolonged delay in cell killing . These results suggested a hypothesis, which remains unproven, that E4orf4 plays a role in the death of infected cells by apoptosis. Death of infected cells by apoptosis could aord several survival advantages, and this mechanism may be common to many viruses (Roulston et al., 1999; Teodoro and Branton, 1997) . The in¯am-matory response would be reduced because apoptotic cells are compartmentalized into lipid vesicles that are taken up rapidly by neighboring cells. This eect would not only lessen the immune response, but also facilitate receptor-independent spread of the virus. Such progeny viruses would also be protected from host antibodies and proteases. As discussed below, E4orf4 killing appears to be selective for cancer cells; however, E4orf4 has evolved in the presence of the E1A oncogene, which may establish suitable conditions for induction of apoptosis in lytically-infected cells. If E4orf4 killing plays a role in virus release, why do adenovirus-infected cells not die earlier, as E4orf4 is expressed at early times? First, even when expressed alone at much higher levels than in infected cells, E4orf4 takes 24 ± 48 h to cause signi®cant cell death. Second, the Bcl-2-like E1B19K protein may delay cell death, as both Bcl-2 and Bcl-X L have been suggested to reduce E4orf4-induced cell killing . And third, although E4orf4 is highly toxic, it is not sucient for the ecient killing of infected cells. Studies on adenovirus mutants lacking the E3-11.6K protein, which is expressed very late in infection, demonstrated a prolonged delay in cell killing even in the presence of E4orf4. Further experiments are required to understand the mechanism of adenovirus-induced death of infected cells and the potential cooperation between E4orf4 and E3-11.6K.
Binding to PP2A is essential for cell killing by E4orf4
As discussed above, E4orf4 binds to the Ba subunit of PP2A and some of its biological eects appear to involve PP2A. To determine the role of this interaction in E4orf4 killing, two groups have conducted genetic studies in which the ability of E4orf4 mutant proteins to bind the Ba subunit and to induce cell killing were compared. Genetic analysis of E4orf4 is dicult as deletion of even short E4orf4 coding sequences yields largely non-functional and often unstable products (Marcellus et al., 2000) . Thus both groups generated a series of point mutations in the E4orf4 coding sequence, both randomly, and by selective mutagenesis aecting residues that are highly conserved in all adenovirus serotypes (Shtrichman et al., 1999; Marcellus et al., 2000) . Both studies indicated a high degree of correlation between binding to PP2A and induction of cell death. That is, mutant E4orf4 proteins that fail to associate with C subunit or with high levels of PP2A phosphatase actiity or that bind very poorly or not at all to the Ba subunit are highly defective for killing. One of these studies, which employed a much larger array of mutants, found that two mutant classes were apparent: class I mutants (mapping largely between residues 51 ± 89) that fail to bind Ba and fail to kill; and class II mutants that interact with Ba at fairly normal levels but are defective for killing (Marcellus et al., 2000) . Further support for the requirement of the Ba subunit was obtained in studies showing that expression of antisense RNA speci®c for Ba transcripts appeared to inhibit E4orf4 cell killing (Shtrichman et al., 1999) . These results indicate that binding to the Ba subunit is absolutely required for E4orf4-mediated cell death and thus that PP2A is the major target. The existence of class II mutants could suggest that Ba binding may not be sucient and that a second E4orf4 function exists; however, it is possible that although binding takes place, it is non-functional in terms of eliciting appropriate eects on PP2A.
Speci®city of B subunit binding
Several kinds of studies have indicated that association of E4orf4 with PP2A is via an interaction with the B subunit. Although binding to the Ba subunit of PP2A has been well established and found to take place in the yeast two hybrid system (Z Zhang, RC Marcellus and PE Branton, unpublished), it has not yet been shown rigorously whether this interaction is direct or via an intermediary protein. Studies with recombinant proteins should resolve this issue. As multiple B subunits exist in four families that share little sequence homology, it was of interest to determine the speci®city of the E4orf4 interaction. In one study conducted in E1A/E1B-transformed human 293 cells, E4orf4 binding was also detected with members of the B'(B56) family of subunits (Shtrichman et al., 2000) . Although mutant analysis indicated that such binding was not involved in E4orf4-mediated cell killing, these observations raise the possibility that E4orf4 elicits other functions via PP2A holoenzymes containing B56 subunits. Our group has also analysed B subunit binding, using H1299 human lung carcinoma cells. Although high levels of binding of E4orf4 were detected with all four highly related members of the B(B55) family (i.e. Ba, Bb, Bg and Bd), none was detected with any members of the B'(B56), B'' or B''' subunit families, which are largely unrelated to B55 proteins (Marcellus et al., submitted) . It is possible that the failure to detect binding with B56 subunits is related to dierences in antibodies or positioning of epitope tags on E4orf4 or B56 products used in binding analyses; however, after extensive eorts, such does not appear to be the case. It is also possible that B56 binding is aected by factors that dier between 293 and H1299 cells. Thus this issue remains unresolved.
Analysis of the apoptotic pathway induced by E4orf4
As mentioned earlier, E4orf4 induces most of the classic hallmarks of apoptosis; however, important dierences from most other inducers exist. Treatment of CHO cells expressing E4orf4 under an inducible promoter with caspase inhibitor zVAD-fmk had little eect on cell death following induction of E4orf4 expression . Further, no induction of caspase-3 or PARP cleavage was apparent in these cells, suggesting that E4orf4-induced apoptosis is caspase independent. More recently, this question has been re-addressed using cells transfected with plasmid DNA expressing E4orf4 (Livne et al., 2001) . In p53-null human H1299 cancer cells, some induction of caspase-3 activity was detected as was release of cytochrome c from mitochondria, a hallmark of caspase activation. In E1A/E1B-expressing human 293 cells, E4orf4-induced apoptosis, as measured by DAPI staining of aberrant nuclei, was diminished by overexpression of a caspase-8 dominant-negative mutant, an eect not seen with a similar caspase-9 mutant. These results suggest that E4orf4 could function through a caspase-8 pathway similar to death receptors. Our group has been addressing this question using a dierent approach, with apparently dierent ®ndings (Szymborski and PE Branton, in preparation). Cells were infected with adenovirus vectors expressing inducible E4orf4 or the pro-apoptotic proteins p53 or tBID. Caspase activation was assessed by Western blotting to detect the presence of cleaved, activated caspases. In H1299 cells, whereas p53 induced massive activation of caspases, expression of E4orf4 failed to activate caspases 1, 2, 3, 6, 7, 8 or 9 in dying cells. Similar results were also obtained in 293 cells using tBID as a positive control. In addition, whereas both tBID and p53 induced release of cytochrome c from mitochondria, E4orf4 did not. The reasons for the discrepancies between these two studies could relate to dierences between DNA transfection and infection with viral vectors, or to dierences in cell density or culture conditions during the experiments. Nevertheless, the possibility exists that E4orf4 may be capable of inducing either caspase-independent or -dependent pathways. Thus, the uniqueness of the E4orf4 apoptosis pathway remains unresolved.
E4orf4 kills cancer cells selectively
Using transformed and primary normal rat cells, Shtrichman et al. (1999) suggested that E4orf4 may kill oncogenic but not normal rat cells. The latter were found to become more susceptible to killing by expression of certain activated oncogenes. Our group has examined over 40 human cancer cell lines representing most major classes of human tumors and found that E4orf4 induces massive cell death in all lines tested (Marcellus et al., submitted) . Interestingly, E4orf4 had little eect on about a dozen primary human cell types derived from various tissues. Cell death in these studies was measured by inhibition of cell growth, and thus E4orf4 killing was cancer cellspeci®c and not related to dierences in proliferation. Studies were also conducted to determine the eect of E4orf4 on growth of human tumor xenografts in mice in vivo. E4orf4 was expressed in tumors by injection of a tetracycline-inducible E4orf4 adenovirus vector in mice given doxacyclin in drinking water. In the case of both C33A and H1299 human tumor cells, expression of E4orf4 caused a signi®cant reduction in tumor size and progression. The eect was far more signi®cant than that obtained using an adenovirus vector expressing p53, a leading candidate for human cancer gene therapy. Thus E4orf4 represents a major potential tool in cancer therapy, either individually or in combination with other genes or treatments.
Why does E4orf4 exhibit cancer cell speci®city? The favored hypothesis is that expression of activated oncogenes or inactivated tumor suppressor genes in cancer cells supply essential signals that trigger cell death once the defective apoptotic signaling machinery in cancer cells has been reinstated by E4orf4. As such upstream signals are not present in normal cells, these cells are resistant to E4orf4 killing. It is also possible that all cancer cells contain higher levels of E4orf4 targets or that these targets or E4orf4 itself are more eectively modi®ed post-translationally or localized in cancer cells. Further understanding of this speci®city must await new insights into the mechanism of action of E4orf4.
Intracellular localization of E4orf4
E4orf4 is found in high quantities in cell nuclei following overexpression: however, signi®cant amounts, especially at later times, are also present in the cytoplasm and associated with cytoplasmic components (MJ Miron, J Lavoie and PE Branton, unpublished) . Although the localization of PP2A B subunits can vary during the cell cycle, the Ba subunit has been found in association with both microtubules and vimentin (Sontag et al., 1995; Turowski et al., 1999) . B'(B56) family members have been found both in the cytoplasm and the nucleus (McCright et al., 1996b) . Preliminary studies using traditional immunouorescence microscopy of cells expressing E4orf4 and various epitope-tagged B subunits indicated a high degree of apparent co-localization of E4orf4 with both the Ba subunit and B'(B56) family members, especially in the cytoplasm (Shtrichman et al., 2000) . These results suggest that the primary targets for E4orf4-PP2A action may be cytoplasmic, although eects on nuclear targets cannot be ruled out. Further studies using E4orf4 proteins fused to speci®c targeting signals could be of value to better de®ne the sites of action of E4orf4, and such studies are underway.
E4orf4, Src family kinases and extranuclear apoptosis
A recent study has demonstrated that E4orf4 can initiate caspase-independent extranuclear apoptosis through a dysregulation of Src family kinases (Lavoie et al., 2000) . Extranuclear apoptosis or anoikis generally occurs when cells lose integrin-mediated attachments to the extracellular matrix (ECM). These cell-ECM attachments promote the assembly of signaling molecules such as Src family kinases and focal adhesion kinase (FAK) to focal adhesion sites, where they then activate downstream survival pathways (Frisch and Ruoslahti, 1997; Giancotti, 1997) . Extranuclear apoptosis occurs in three steps, the ®rst being the release stage, which involves reorganization of focal adhesions and actin to give cells a rounder morphology, after which membrane blebbing and ®nally condensation into apoptotic bodies occurs (Mills et al., 1999) . While E4orf4 expressing cells are able to bind to ECM proteins, E4orf4 appears to interfere with downstream signals that promote cell spreading and survival. E4orf4 was found to associate and colocalize with Src family kinases and these complexes contain the PP2A catalytic subunit (Lavoie et al., 2000) . Whether the E4orf4-Src interaction is direct or mediated by other proteins remains to be determined. Src kinase activity appears to aect the distribution of E4orf4 in cells. About 30% of E4orf4 is normally associated with the cytoskeleton; however, in the presence of activated c-Src or v-Src this level increases 2 ± 3-fold. The authors suggest that this massive translocation of E4orf4 may contribute to the triggering of cell death. Src activity also positively correlates with the amount of E4orf4-induced membrane blebbing and nuclear condensation. PP2, a chemical inhibitor speci®c to Src family kinases, signi®cantly inhibited the number of apoptotic E4orf4-expressing cells. While E4orf4 does not aect the in vitro kinase activity of c-Src, it appears to modulate Src-dependent tyrosine phosphorylation of speci®c substrates with some having higher (FAK and paxillin) and others lower (cortactin) levels of tyrosine phosphorylation. Expression of E4orf4 also correlates with a dramatic relocalization of tyrosine phosphorylated proteins, actin ®bers and cortactin (Lavoie et al., 2000) . The proposed model is that E4orf4 can interfere with Src/FAK signaling to promote the improper assembly of focal adhesions and ultimately the loss of survival signals. This eect would be accompanied by changes in the actin cytoskeleton, resulting in morphological and structural changes and membrane blebbing typical of apoptosis. It is still unclear how E4orf4 modulates Src kinase activity, becomes relocated in the presence of activated Src, or rearranges the actin cytoskeleton.
Mechanism of action of E4orf4
Interactions of E4orf4 with the Ba subunit (and/or possibly other members of the B55 family) are required for E4orf4-induced cell killing, and thus the major questions in determining the mechanism of action lie in de®ning the eects of E4orf4 on PP2A function and the targets of E4orf4-modi®ed PP2A enzyme. Clearly E4orf4 can enhance the hypophosphorylation of several proteins, including c-Fos, E1A, E4F and SR factors, and alter c-Src-dependent phosphorylation patterns; however, it is neither clear if these proteins are direct targets for E4orf4-PP2A complexes, nor if these events are related to cell killing. Although binding low levels of PP2A activity by E4orf4 appears to be sucient to kill some cells (Shtrichman et al., 1999) , our work with many cell types has clearly indicated that cell killing increases with increasing levels of E4orf4 expression (Marcellus et al., submitted) . These results suggest a stoichiometric relationship between E4orf4 and PP2A, possibly related to the ability of E4orf4 to locate appropriate PP2A holoenzymes, or a necessary shift in the global balance of normal and E4orf4-modi®ed B55-PP2A. E4orf4 could alter the overall phosphatase activity of PP2A following binding to the Ba subunit, or more likely, modify the substrate speci®city of such enzymes. Several mechanisms for repro®ling PP2A speci®city could be possible, including: relocalization of PP2A by E4orf4 to preferred targets for cell death; modi®cation of the Ba subunit to enhance activity against certain selective substrates; or binding of proapoptotic substrates to target them to PP2A. At present very little information exists to distinguish between these possibilities. In addition to B subunits, E4orf4 appears also to bind selective SR factors (Estmer-Nilsson et al., 2001) ; however, several additional as yet unidenti®ed proteins co-immunoprecipitate with E4orf4 (MJ Miron and PE Branton, unpublished) . Identi®cation of these species and further studies on the enzymatic activity of E4orf4-PP2A are required to provide new insights. In addition to these biochemical studies, downstream targets of E4orf4 may be elucidated through genetic approaches. In this regard, studies in yeast may be highly informative because of the availability of powerful genetic techniques in this organism.
E4orf4 in Saccharomyces cerevisiae
PP2A enzymes of Saccharomyces cerevisiae greatly resemble mammalian PP2A with respect to organization, substrate speci®city, and sensitivity to inhibitors (Cohen et al., 1989) . A duplicated gene encodes two forms of the catalytic C subunit, Pph21 and Pph22 (Sneddon et al., 1990) , that share 89% amino acid sequence identity. Both are at least 75% identical to the human C subunit peptide sequences (Costanzo et al., 2000) , but contain a unique acidic amino terminal region of unknown function (Ronne et al., 1991) . These subunits are dispensable for cell growth when deleted individually, but strains lacking both, as well as a related gene, PPH3, are non-viable (Ronne et al., 1991) . Temperature sensitive mutants have shown that the catalytic subunit is important for mitosis, cell wall integrity, and polarized growth (Evans and Stark, 1997). TPD3 encodes the only A subunit, and like its mammalian counterpart it contains 15 non-identical repeats of 39 residues (van Zyl et al., 1992) , termed HEAT (huntingtin-elongation-Asubunit-TOR) motifs, that probably mediate protein-protein interactions (Groves et al., 1999; Hemmings et al., 1990) . tpd3 strains grow poorly and are both cold and heat sensitive, having morphological defects similar to cdc55 cells at low temperatures and being defective for RNA polymerase III transcription at elevated temperatures (van Zyl et al., 1992) .
Only two B-type regulatory subunits exist in yeast and are encoded by CDC55 and RTS1, representing the B and B' families, respectively (Healy et al., 1991; Shu et al., 1997) . Cdc55 is 47% identical and 61% similar to the human Ba subunit of PP2A (Costanzo et al., 2000) . cdc55 deletion strains are cold sensitive and produce abnormally elongated cells due to defects in cytokinesis and/or septation, thus implicating PP2A in cell morphogenesis (Healy et al., 1991) . Cdc55 has also been shown to play a role in the cell cycle and appears to function at the spindle checkpoint as well as to be required for the proper regulation of Swe1 kinase (Wang and Burke, 1997; Yang et al., 2000) . Rts1 shares over 50% identity with mammalian B' subunits (Costanzo et al., 2000) . rts1 deletion strains are temperature sensitive for growth, with the majority of cells accumulating in G2/M with a single undivided nucleus (Shu et al., 1997) . Rts1 also regulates the global stress response in yeast (Evangelista et al., 1996) . Rts1 and Cdc55 are not functionally redundant PP2A subunits as Rts1 does not rescue cold sensitivity of cdc55 cells, but actually enhances the morphological abnormalities of this mutant (Shu et al., 1997) .
S. cerevisiae provides a genetically tractable model system in which to study E4orf4 functions. E4orf4 expression was shown to promote irreversible growth arrest in yeast Roopchand et al., 2001) , promoting an elongated morphology in cells arrested or delayed in the G2/M phase of the cell cycle, as demonstrated by FACS analysis and the presence of elevated Cdc28/Cdk1 kinase activity (Roopchand et al., 2001; Kornitzer et al., 2001) . As with Ba in mammalian cells, E4orf4 interacts with the Cdc55 subunit and through this interaction recruits the entire active PP2A complex containing Pph21/22 and Tpd3 (Roopchand et al., 2001) . Evidence demonstrating the necessity of the B subunit for E4orf4 function in mammalian cells has been correlative thus far (Marcellus et al., 2000; Shtrichman et al., 1999) . Using the yeast system a direct requirement for the B subunit has been clearly demonstrated, as whereas E4orf4 is fully toxic in an rts1 deletion strain, the majority of E4orf4 toxicity is abolished in a cdc55 deletion strain (Roopchand et al., 2001; Kornitzer et al., 2001) ; however, low levels of growth inhibition were still detected in the absence of Cdc55, suggesting that E4orf4 may have PP2A-independent functions (Roopchand et al., 2001) . In the absence of Cdc55, E4orf4 does not interact with the A and C subunits, nor does it associate with any detectable PP2A phosphatase activity, thus con®rming the importance of Cdc55 for recruitment of PP2A and indicating that no interaction takes place with B'-like Rts1 subunits (Roopchand et al., 2001) . In wild-type yeast both class I (R81A/F84A) and class II (K88A) E4orf4 mutants induce a partial eect on cell growth similar to that of wild type E4orf4 in cdc55 deletion strains, even though binding to Cdc55 was undetectable with the former and similar to wild type E4orf4 with the latter (Roopchand et al., 2001) . Taken together, these results again suggest that E4orf4 elicits Cdc55-independent eects. Further studies using yeast genetics should allow identi®cation of E4orf4 downstream targets, and this information may shed light on the mechanism of induction of p53-independent killing of transformed cells.
Little is yet understood about the mechanism of E4orf4 toxicity in yeast, although one study may provide some insights. Induction of growth arrest in yeast was found to be associated with an accumulation of reactive oxygen species (Kornitzer et al., 2001) . Further, genetic studies using yeast mutants defective in mitosis have suggested an involvement of products required for mitosis, including Cdc28/Cdk1 and anaphase-promoting complex/cyclosome (APC/C). E4orf4 was found to inhibit APC/C activity, possibly through a direct interaction with APC/C, while enhancing that of Cdc28/Cdk1 (Kornitzer et al., 2001) . Although these observations need to be con®rmed by other laboratories, they may represent a signi®cant step in our understanding of E4orf4 action.
Future research and therapeutic potential of E4orf4
The discovery that B(B55) subunits of PP2A represent the primary targets in E4orf4-induced p53-independent apoptosis has provided a major insight into the mechanism of action of E4orf4. Nevertheless we understand little of the consequences of this interaction or whether or not the intracellular location of E4orf4-PP2A complexes is important. It will be important to determine what eect this interaction has on PP2A enzymatic activity, and to identify the speci®c targets involved in the onset of cell death. Cell death could be induced by increased or decreased PP2A-mediated dephosphorylation of relatively few substrates (perhaps those linked directly with cell survival or cell death pathways), or it may result from more global eects on a wide range of substrates in multiple pathways causing an accumulated decline in cell viability. Death could also result indirectly as a consequence of changes in transcription, splicing, or translation induced by E4orf4. Thus analysis of changes in the patterns of gene and protein expression in response to E4orf4 using new technologies may be informative. It is also likely that genetic analyses to identify suppressors of E4orf4-induced killing using either mammalian or yeast systems will prove signi®cant. Identi®cation of additional E4orf4-binding proteins should also provide insights. All of these approaches are now underway in several laboratories.
Additional questions concern the identi®cation of a possible second function of E4orf4 in cell killing, and whether E4orf4-induced cell death plays a role in the replication cycle of adenoviruses. As caspase activation and cytochrome c release are not stimulated by E4orf4 in at least some systems, E4orf4 should also provide insights into novel mechanisms of apoptosis. Further, the determination of the mechanism of the dierential susceptibility of normal and cancer cells could provide insights for the development of new anti-cancer drugs.
E4orf4 has great potential in cancer therapy. A majority of human cancers contain mutations that inactivate p53, and many other cancers are probably defective in downstream components of the p53 pathway, including Arf. As many current therapies rely on p53-dependent cell killing, these treatments are only of limited value in these cases. E4orf4 kills a wide range of cancer cells independently of p53, and thus could be eective in all cancers, regardless of p53 status. Therefore the use of E4orf4 as a gene therapy agent or in the development of small molecule drugs that mimic E4orf4 function could yield highly eective and speci®c treatments for human cancer. We believe that many of these issues will be resolved in the near future.
